6-Bromothieno[3,2-d]pyrimidin-4(3H)-one

Catalog No.: 
ACRQXI907
CAS No.: 
215927-36-9
Molecular Formula: 
C6H3BrN2OS
Molecular Weight: 
231.07
6-Bromothieno[3,2-d]pyrimidin-4(3H)-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$78.00In stockInquiry
250mg98%$99.00In stockInquiry
1g98%$251.00In stockInquiry
5g98%$753.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-Bromothieno[3,2-d]pyrimidin-4(3H)-one
IUPAC Name6-bromothieno[3,2-d]pyrimidin-4(3H)-one
MDL No.MFCD17677443
Molecular FormulaC6H3BrN2OS
Molecular Weight231.07
SMILESO=C1C2=C(C=C(Br)S2)N=CN1
InChI KeyIJSCGMBLRLDHPZ-UHFFFAOYSA-N
Synonym6-BROMO-1H-THIENO[3,2-D]PYRIMIDIN-4-ONE;6-BroMo-3H-thieno[3,2-d]pyriMidin-4-one;6-BroMothieno[3,2-d]pyriMidin-4(3H)-one;Thieno[3,2-d]pyrimidin-4(3H)-one, 6-bromo-
CAS No.215927-36-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302
Precautionary Statement(s)
P264-P270-P301+P312-P330-P501

Synthetic Route by SureRoute

1. ACRQXI907 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEDMW612 route compound structure diagram
    ACEDMW6126108-23-2In Stock
  4. Then
  5. ACRQXI907 route product structure diagram
    ACRQXI907215927-36-9In Stock
Inquiry

2. ACRQXI907 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRQXI907 route product structure diagram
    ACRQXI907215927-36-9In Stock
Inquiry

3. ACRQXI907 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRQXI907 route product structure diagram
    ACRQXI907215927-36-9In Stock
Inquiry

Comments (0)